Molecular Imaging Probes for Preclinical and Clinical Research
A reliable, cost-effective source for PET and SPECT radiopharmaceuticals
and radiolabeling services.
CPDC provides high-quality molecular imaging probes for preclinical and clinical research in the following areas:
- Disease diagnosis, staging and treatment monitoring;
- Delivery of therapeutics;
- Imaging biomarkers in drug development.
Offering a broad range of capabilities in probe discovery, development and distribution, CPDC is uniquely qualified to help you achieve your project goals. Our experienced, dedicated teams work collaboratively with you to understand your project requirements and produce existing or novel radiopharmaceuticals using the industry’s most advanced synthesis, analysis and manufacturing equipment.
Researchers at hospitals, private clinics, pharmaceutical companies and academic institutions trust CPDC to provide the scientific expertise and manufacturing infrastructure needed to produce superior quality molecular imaging probes that meet or exceed stringent specification and timelines.
Investigational Imaging Probes*
CPDC is capable of formulating and manufacturing a broad range of molecular imaging probes for use in diagnostic and drug development applications including:
- 18F-Fluorothymidine (18F-FLT)
- 18F -Fluoroazomycin Arabinoside (18F -FAZA)
- 18F -Fluorocholine (18F -FCH)
- 18F -Sodium Fluoride (18F -NaF)
- 123I-Iodohippuric Acid
We are able to access a wide range of isotopes, enabling our teams to produce short- and long-lived imaging probes that can leverage the unique strengths of two major imaging modalities – positron emission tomography (PET) and single photon emission computed tomography (SPECT) cameras.
Dedicated Teams Focused on Maximizing Quality, Value and Safety of Molecular Probes
From new targets to ligands to radiolabeling processes, CPDC’s discovery team provides comprehensive capabilities to successfully develop and translate PET, SPECT and therapeutic radiopharmaceuticals for clinical use.
Rigorous attention is given to process validation and product quality. Each batch is fully documented and auditable. On-site quality control and microbiology teams rapidly confirm product quality.
Expert regulatory support and document submissions for all phases of probe development and commercialization.
All products are manufactured according to Good Manufacturing Practices (GMP) in a facility that is licensed and inspected by Health Canada, assuring high product quality, yields, purity and sterility.
Reliable on-time delivery through a direct distribution channel.
CPDC has validated and manufactured two emerging probes for clinical trials in Ontario.
18F-Fluoroazomycin Arabinoside (18F-FAZA)*:
Rapidly growing malignant tumours often become hypoxic, a condition where the tumour outgrows its blood supply and becomes difficult to treat. Following validation through clinical testing, PET imaging with FAZA could help physicians to accurately visualize tumour hypoxia. Like other probes produced by CPDC, FAZA is manufactured using an automated process in our GMP facility, which assures high product quality and efficacy.
Used to monitor tumour proliferation, FLT has potential to be an important agent for assessing the success of treatment. In 2009, CPDC became Ontario’s first GMP-producer of FLT for Health Canada approved clinical trials. CPDC follows rigorous procedures to develop manufacturing processes, validate quality control methods and perform product stability testing. The automated production process assures consistent product yield and long shelf life.
(*Market authorization not yet obtained)
Contact us today to learn more about CPDC investigational probes.
905.525.9140 x 21212